|
gptkbp:instance_of
|
gptkb:pharmaceuticals
gptkb:Fullmetal_Alchemist
|
|
gptkbp:administered_by
|
intravenous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
L01 CA01
|
|
gptkbp:brand
|
gptkb:Oncovin
|
|
gptkbp:can_be_combined_with
|
other chemotherapy agents
|
|
gptkbp:case_types
|
gptkb:Oncology
gptkb:non-Hodgkin_lymphoma
gptkb:Wilms_tumor
gptkb:neuroblastoma
|
|
gptkbp:casnumber
|
57-22-7
|
|
gptkbp:chemical_formula
|
C46 H58 N4 O10
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
peripheral neuropathy
severe liver disease
|
|
gptkbp:developed_by
|
gptkb:Periwinkle_plant
|
|
gptkbp:discovered_by
|
1960s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vincristine
|
|
gptkbp:interacts_with
|
other neurotoxic agents
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:mechanism_of_action
|
inhibits microtubule formation
|
|
gptkbp:produced_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:related_to
|
gptkb:vinblastine
|
|
gptkbp:research_focus
|
long-term effects
combination therapies
drug resistance
new formulations
pediatric dosing
|
|
gptkbp:shelf_life
|
2 years
|
|
gptkbp:side_effect
|
nausea
vomiting
constipation
hair loss
neuropathy
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
treating cancer
|
|
gptkbp:used_in
|
pediatric oncology
|
|
gptkbp:weight
|
825.0 g/mol
|
|
gptkbp:bfsParent
|
gptkb:cyclophosphamide
|
|
gptkbp:bfsLayer
|
6
|